Grant

This 5-year grant will address the mechanisms of resistance to chemotherapy in highly aggressive breast cancers using cutting-edge methodologies, including testing our recently developed LOX inhibitors. NEW positions are available for highly motivated postdocs and graduate students.

This work aims to enhance the efficacy of antibody-drug conjugate (ADC) therapy in aggressive breast cancer. Here is the press release: https://marykayashfoundation.org/what-we-do/cancer-research/grant-recipients/

Our R01 grant aiming at blocking tumor growth and metastasis in highly aggressive breast cancers has been funded. In this exciting project, we will target highly aggressive breast cancers with our newly developed inhibitor.